礼来公司旗下药物Jaypirca（Pirtobrutinib）在针对既往接受过治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的研究中，当联合Venetoclax限时治疗方案使用时，展现出显著的疗效优势。数据显示，该联合疗法能够将患者疾病进展或死亡的风险大幅降低45%。这一结果凸显了该组合疗法作为此类患者群体潜在重要治疗选择的巨大前景。
礼来公司旗下药物Jaypirca（Pirtobrutinib）在针对既往接受过治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的研究中，当联合Venetoclax限时治疗方案使用时，展现出显著的疗效优势。数据显示，该联合疗法能够将患者疾病进展或死亡的风险大幅降低45%。这一结果凸显了该组合疗法作为此类患者群体潜在重要治疗选择的巨大前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.